Strategic Partnerships

Depomed utilizes an aggressive partnering strategy to support its effort to build a portfolio of enhanced pharmaceutical products for large patient populations. The company’s partnering strategy is comprised of two key components – 

  • Outlicense internally developed drugs to commercialization partners worldwide, while retaining rights to market products on its own to select market segments should it elect to do so;
  • Collaborate with companies looking to utilize AcuForm™ delivery technology to enhance their own pharmaceutical products and possibly extend the product’s lifecycle.

Partnerships in Place

The following is a list of some of the commercialization and development partnerships Depomed currently has in place. To learn more about these partnerships, please visit the press release section of this website.

Commercialization Partnerships

Watson Pharmaceuticals
Co-promotion agreement established in July 2007 for the U.S. commercialization of ProQuin® XR (ciprofloxacin hydrochloride) for uncomplicated urinary tract infections to urologists and long-term care physicians.

Development Partnerships

Biovail Corporation
License and development agreement established in February 2007 granting Biovail an option to license AcuForm delivery technology to develop and commercialize up to two pharmaceutical products.

Patheon Inc.
Collaborative agreement established in August 2006 providing Patheon with access to AcuForm technology for the purpose of formulating, developing or improving pharmaceutical products for the company’s clients and collaborative partners.

Supernus Pharmaceuticals, Inc.
Collaborative agreement established in September 2006 providing Supernus Pharmaceuticals with access to AcuForm technology for the development of a product candidate (undisclosed compound) through a Phase 1 clinical study.

Partnership Opportunities

Depomed welcomes inquiries from companies interested in working together to develop enhanced pharmaceutical products, or to commercialize Depomed’s approved products.

The following is a list of partnering opportunities currently available with Depomed. To learn more, please contact the company’s business development department at busdev@depomedinc.com.

Commercialization Opportunities

  • Glumetza for Type 2 Diabetes (US)
  • Proquin XR for Uncomplicated Urinary Tract Infections
     - (excluding urology/ Ob/Gyn / Long-term care)

Development Opportunities

  • Gabapentin GR® for Multiple Indications
    • Postherpetic Neuralgia 
    • Diabetic Peripheral Neuropathy 
    • Menopausal Hot Flashes